Halozyme Therapeutics Inc (HALO) — Free Cash Flow Generation Index

Latest as of September 2025: 0.98x

Halozyme Therapeutics Inc (HALO) has a Free Cash Flow Generation Index of 0.98x as of September 2025. Free cash flow of $175.57 Million represents 1% of operating cash flow ($178.60 Million). See Halozyme Therapeutics Inc (HALO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.98x
Free Cash Flow / Operating CF

Free Cash Flow

$175.57 Million
USD

Operating Cash Flow

$178.60 Million
USD

Capital Expenditures

$3.03 Million
USD

Halozyme Therapeutics Inc Free Cash Flow Generation Index (2006–2024)

Historical FCF Generation Index trend for Halozyme Therapeutics Inc across 7 annual periods. Explore HALO cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Halozyme Therapeutics Inc (2006–2024)

Year-by-year Free Cash Flow Generation Index for Halozyme Therapeutics Inc. For the full company profile including market capitalisation, see Halozyme Therapeutics Inc market cap and net worth.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2024 0.98x $468.37 Million $479.06 Million $10.70 Million ▲ +1.8%
2023 0.96x $373.28 Million $388.57 Million $15.29 Million ▼ -2.0%
2022 0.98x $235.30 Million $240.11 Million $4.81 Million ▼ -1.5%
2021 1.00x $297.98 Million $299.44 Million $1.46 Million ▲ +4.2%
2020 0.95x $52.95 Million $55.45 Million $2.50 Million ▼ -3.5%
2017 0.99x $132.70 Million $134.05 Million $1.35 Million ▲ +4.4%
2006 0.95x $6.71 Million $7.08 Million $364.80K
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).